Inhibition of PI3K/mTOR pathways in glioblastoma and implications for combination therapy with temozolomide

A phase II trial of erlotinib in patients with recurrent malignant gliomas and nonprogressive glioblastoma multiforme postradiation therapy

(2011) J. J. Raizer et al.   NEURO-ONCOLOGY

Safety and efficacy of erlotinib in first-relapse glioblastoma: a phase II open-label study

(2010) W. K. A. Yung et al.   NEURO-ONCOLOGY

Potential therapeutic targets for chordoma: PI3K/AKT/TSC1/TSC2/mTOR pathway

(2009) N Presneau et al.   BRITISH JOURNAL OF CANCER

Mammalian target of rapamycin (mTOR) is involved in the survival of cells mediated by chemokine receptor 7 through PI3K/Akt in metastatic squamous cell carcinoma of the head and neck

(2009) Fa-Yu Liu et al.   BRITISH JOURNAL OF ORAL & MAXILLOFACIAL SURGERY

Antimyeloma Activity of the Orally Bioavailable Dual Phosphatidylinositol 3-Kinase/Mammalian Target of Rapamycin Inhibitor NVP-BEZ235

(2009) D. W. McMillin et al.   CANCER RESEARCH

Advances in Development of Phosphatidylinositol 3-Kinase Inhibitors

(2009) Dexin Kong et al.   CURRENT MEDICINAL CHEMISTRY

PI3K and mTOR inhibitors—a new generation of targeted anticancer agents

(2009) Saskia Brachmann et al.   CURRENT OPINION IN CELL BIOLOGY

Aberration of the PI3K/AKT/mTOR signaling in epithelial ovarian cancer and its implication in cisplatin-based chemotherapy

(2009) Hai-Yan Zhang et al.   European Journal of Obstetrics & Gynecology and Reproductive Biology

Glioblastoma multiforme: a review of where we have been and where we are going

(2009) Cory Adamson et al.   EXPERT OPINION ON INVESTIGATIONAL DRUGS

Genomic aberrations in 80 cases of primary glioblastoma multiforme: Pathogenetic heterogeneity and putative cytogenetic pathways

(2009) Hanne-Sofie S. Dahlback et al.   GENES CHROMOSOMES & CANCER

Molecular Predictors of Progression-Free and Overall Survival in Patients With Newly Diagnosed Glioblastoma: A Prospective Translational Study of the German Glioma Network

(2009) Michael Weller et al.   JOURNAL OF CLINICAL ONCOLOGY

Randomized Phase II Trial of Erlotinib Versus Temozolomide or Carmustine in Recurrent Glioblastoma: EORTC Brain Tumor Group Study 26034

(2009) Martin J. van den Bent et al.   JOURNAL OF CLINICAL ONCOLOGY

Honokiol-mediated Inhibition of PI3K/mTOR Pathway

(2009) Courtney Crane et al.   JOURNAL OF IMMUNOTHERAPY

Activation of PI3K/mTOR pathway occurs in most adult low-grade gliomas and predicts patient survival

(2009) Sean M. McBride et al.   JOURNAL OF NEURO-ONCOLOGY

Phase II trial of erlotinib with temozolomide and radiation in patients with newly diagnosed glioblastoma multiforme

(2009) David M. Peereboom et al.   JOURNAL OF NEURO-ONCOLOGY

Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial

(2009) Roger Stupp et al.   LANCET ONCOLOGY

NVP-BEZ235, a novel dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor, elicits multifaceted antitumor activities in human gliomas

(2009) T.-J. Liu et al.   MOLECULAR CANCER THERAPEUTICS

Dual targeting of AKT and mammalian target of rapamycin: A potential therapeutic approach for malignant peripheral nerve sheath tumor

(2009) C. Y. Zou et al.   MOLECULAR CANCER THERAPEUTICS

The pyridinylfuranopyrimidine inhibitor, PI-103, chemosensitizes glioblastoma cells for apoptosis by inhibiting DNA repair

(2009) M -A Westhoff et al.   ONCOGENE

Identification of survival-related genes of the phosphatidylinositol 3′-kinase signaling pathway in glioblastoma multiforme

(2008) Yolanda Ruano et al.   CANCER

Yes and PI3K Bind CD95 to Signal Invasion of Glioblastoma

(2008) Susanne Kleber et al.   CANCER CELL

NVP-BEZ235, a Dual PI3K/mTOR Inhibitor, Prevents PI3K Signaling and Inhibits the Growth of Cancer Cells with Activating PI3K Mutations

(2008) V. Serra et al.   CANCER RESEARCH

Phase I/II Trial of Erlotinib and Temozolomide With Radiation Therapy in the Treatment of Newly Diagnosed Glioblastoma Multiforme: North Central Cancer Treatment Group Study N0177

(2008) Paul D. Brown et al.   JOURNAL OF CLINICAL ONCOLOGY

Phase II Study of Erlotinib Plus Temozolomide During and After Radiation Therapy in Patients With Newly Diagnosed Glioblastoma Multiforme or Gliosarcoma

(2008) Michael D. Prados et al.   JOURNAL OF CLINICAL ONCOLOGY

Inhibition of PI3K-AKT-mTOR Signaling Sensitizes Melanoma Cells to Cisplatin and Temozolomide

(2008) Tobias Sinnberg et al.   JOURNAL OF INVESTIGATIVE DERMATOLOGY

Comprehensive genomic characterization defines human glioblastoma genes and core pathways

(2008) Roger McLendon et al.   NATURE

Neural Stem Cell Targeting of Glioma Is Dependent on Phosphoinositide 3-Kinase Signaling

(2008) Stephen E. Kendall et al.   STEM CELLS

Antitumor Activity of Rapamycin in a Phase I Trial for Patients with Recurrent PTEN-Deficient Glioblastoma

(2008) Tim F Cloughesy et al.   PLOS MEDICINE